Pheochromocytoma pathophysiology: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 8: | Line 8: | ||
==Pathophysiology== | ==Pathophysiology== | ||
* Pheochromocytoma arises from [[chromaffin cells]] of the [[adrenal medulla]] and [[Sympathetic ganglion|sympathetic ganglia]]. [[Malignant]] and [[benign]] pheochromocytomas share the same [[biochemical]] and [[histological]] features, the only difference is to have a distant spread or be locally invasive. <ref name="pmid10363888">{{cite journal| author=Goldstein RE, O'Neill JA, Holcomb GW, Morgan WM, Neblett WW, Oates JA et al.| title=Clinical experience over 48 years with pheochromocytoma. | journal=Ann Surg | year= 1999 | volume= 229 | issue= 6 | pages= 755-64; discussion 764-6 | pmid=10363888 | doi= | pmc=1420821 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10363888 }}</ref> | * Pheochromocytoma arises from [[chromaffin cells]] of the [[adrenal medulla]] and [[Sympathetic ganglion|sympathetic ganglia]]. [[Malignant]] and [[benign]] pheochromocytomas share the same [[biochemical]] and [[histological]] features, the only difference is to have a distant spread or be locally invasive. <ref name="pmid10363888">{{cite journal| author=Goldstein RE, O'Neill JA, Holcomb GW, Morgan WM, Neblett WW, Oates JA et al.| title=Clinical experience over 48 years with pheochromocytoma. | journal=Ann Surg | year= 1999 | volume= 229 | issue= 6 | pages= 755-64; discussion 764-6 | pmid=10363888 | doi= | pmc=1420821 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10363888 }}</ref> | ||
'''<u>Basic physiology of [[catecholamines]]</u>'''<ref name="pmid1900669">{{cite journal| author=Raz I, Katz A, Spencer MK| title=Epinephrine inhibits insulin-mediated glycogenesis but enhances glycolysis in human skeletal muscle. | journal=Am J Physiol | year= 1991 | volume= 260 | issue= 3 Pt 1 | pages= E430-5 | pmid=1900669 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1900669 }}</ref> | '''<u>Basic physiology of [[catecholamines]]</u>'''<ref name="pmid1900669">{{cite journal| author=Raz I, Katz A, Spencer MK| title=Epinephrine inhibits insulin-mediated glycogenesis but enhances glycolysis in human skeletal muscle. | journal=Am J Physiol | year= 1991 | volume= 260 | issue= 3 Pt 1 | pages= E430-5 | pmid=1900669 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1900669 }}</ref><ref name="pmid3521311">{{cite journal| author=Arnall DA, Marker JC, Conlee RK, Winder WW| title=Effect of infusing epinephrine on liver and muscle glycogenolysis during exercise in rats. | journal=Am J Physiol | year= 1986 | volume= 250 | issue= 6 Pt 1 | pages= E641-9 | pmid=3521311 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3521311 }}</ref> | ||
* [[Epinephrine]] acts on nearly all body tissues. Its actions vary by tissue type and tissue expression of [[adrenergic receptors]]. | * [[Epinephrine]] acts on nearly all body tissues. Its actions vary by tissue type and tissue expression of [[adrenergic receptors]]. | ||
* [[Epinephrine]] is a nonselective agonist of all [[adrenergic receptors]], including the major subtypes [[Alpha-1 adrenergic receptor|α<sub>1</sub>]], [[Alpha-2 adrenergic receptor|α<sub>2</sub>]], [[Β1-adrenoreceptors|β<sub>1</sub>]], [[Beta-2 adrenergic receptor|β<sub>2</sub>]], and [[Beta-3 adrenergic receptor|β<sub>3:</sub>]] | * [[Epinephrine]] is a nonselective agonist of all [[adrenergic receptors]], including the major subtypes [[Alpha-1 adrenergic receptor|α<sub>1</sub>]], [[Alpha-2 adrenergic receptor|α<sub>2</sub>]], [[Β1-adrenoreceptors|β<sub>1</sub>]], [[Beta-2 adrenergic receptor|β<sub>2</sub>]], and [[Beta-3 adrenergic receptor|β<sub>3:</sub>]] | ||
Revision as of 18:29, 31 August 2017
|
Pheochromocytoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pheochromocytoma pathophysiology On the Web |
|
American Roentgen Ray Society Images of Pheochromocytoma pathophysiology |
|
Risk calculators and risk factors for Pheochromocytoma pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2] Mohammed Abdelwahed M.D[3]
Overview
Pheochromocytoma arises from chromaffin cells of the adrenal medulla. On gross pathology, pheochromocytoma has a multinodular and a multicentric pattern of growth. On microscopic histopathological analysis, nesting (Zellballen) pattern composed of well-defined clusters of tumor cells separated by fibrovascular stroma may be seen. It may be benign, malignant, familial(multiple endocrine neoplasia 1 and type 2B) or sporadic. All of these forms have genetic origin depending on a large number of genes, for example, VHL, SDH, NF1, RET genes.
Pathophysiology
- Pheochromocytoma arises from chromaffin cells of the adrenal medulla and sympathetic ganglia. Malignant and benign pheochromocytomas share the same biochemical and histological features, the only difference is to have a distant spread or be locally invasive. [1]
Basic physiology of catecholamines[2][3]
- Epinephrine acts on nearly all body tissues. Its actions vary by tissue type and tissue expression of adrenergic receptors.
- Epinephrine is a nonselective agonist of all adrenergic receptors, including the major subtypes α1, α2, β1, β2, and β3:
- Binding to α1 receptors causes vasoconstriction. Blood vessels with α1-adrenergic receptors are present in the skin, the sphincters of the gastrointestinal system, kidney (renal artery) and brain. During the fight-or-flight response vasoconstriction results in decreased blood flow to these organs.
- Binding to α2 receptors inhibits insulin secretion by the pancreas, stimulates glycogenolysis in the liver and muscle, and stimulates glycolysis and inhibits insulin-mediated glycogenesis in muscle. It suppresses the release of norepinephrine by negative feedback.
- Binding to β2 receptors causes Smooth muscle relaxation in the uterus, GI tract, detrusor urinae muscle of bladder wall, and bronchi. It also causes dilatation of smaller coronary arteries, hepatic artery, arteries to skeletal muscle.
- Binding to β1 receptors causes renin release from juxtaglomerular cells and lipolysis in adipose tissue. It Increases cardiac output by:
- Increase in heart rate in sinoatrial node
- Increase in atrial cardiac muscle contractility
- Increases in contractility and automaticity of ventricular cardiac muscle
- Increases in conduction and automaticity of atrioventricular node
Genetics
- Pheochromocytomas can be familial and occur in patients with multiple endocrine neoplasias (MEN1 and MEN 2B).
- Patients with Von Hippel Lindau disease (VHL) may also develop pheochromocytoma.[6]
- It has autosomal dominant inheritance and has two pathways of tumor pathogenesis. Cluster 1 tumors are noradrenergic. Cluster 2 tumors are adrenergic.[7]
| Familial pheocromocytomas | |
|---|---|
| Cluster 1 (Noradrenergic) | Cluster 2 (Adrenergic) |
|
|
- Patients with the succinate dehydrogenase B mutations are likely to develop a malignant disease.[8]
- Von Hippel-Lindau (VHL) disease
- PCCs arise in about 10–20% of patients with VHL disease.
- VHL tumor suppressor protein is the main cause of the disease. There are more than 500 different germ-line VHL mutations linked to VHL disease have been reported.[9] Missense, nonsense, splice site mutations, microdeletions, and insertions are detected in about two-thirds of the patients.
- The VHL tumor suppressor protein targets especially hypoxia-inducible factor-1 (HIF-1), MMP inhibitors, and atypical protein kinase C.[10]
- HIF-1 is involved in erythropoiesis through its ability to induce transcription of mRNA coding for erythropoietin. it regulates several growth factors, such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF)-beta, and transforming growth factor (TGF)-alpha.[11]
- Deletions in VHL and nonsense and frameshift mutations appear to be more common in type 1 disease, while missense mutations may be more common in type 2 disease.[12] Missense mutations at codon 167 are associated with a particularly high risk of PCC.[13]
- Multiple endocrine neoplasia type 2A
- The RET protein is a transmembrane receptor of the tyrosine kinase family.
- It is expressed in cell lineages derived from the neural crest and has a key role in regulating cell proliferation, migration, differentiation, and survival during embryogenesis.[14]
- The RET receptor can be activated through various factors such as glial-cell-line-derived neurotrophic factor (GDNF), neurturin, artemin, and persephin.[15]
- Germline mutations of the RET proto-oncogene cause constitutive activation of the RET receptor and of intracellular signaling pathways (“gain of function”), ultimately resulting in the cellular transformation.[16]
- Mutations causing loss of function of the RET protein were found to be associated with Hirschsprung's disease, a developmental disorder characterized by the absence of enteric ganglia in the intestinal tract.[17]
- Neurofibromatosis type 1 (NF1)
- The NF1 gene has been localized on chromosome 17qll.2 and encodes its protein product, neurofibromin.[18]
- Most mutations in the NF1 gene result in the truncation of neurofibromin and thus in the loss of functional protein causing the wide spectrum of clinical findings.
- In the absence or at decreased levels of neurofibromin in NF1, signaling is increased through various pathways resulting in the cell proliferation and inhibited apoptosis.[19]
- The NF1 mutations include translocations, splicing, deletions, duplications, insertions, point mutations, and substitutions. NF1 also has a high rate of new mutations of about 50%.
- The GAP (Ras-GTPase-activating protein)-related domain (GRD) is a small part of and has the important role of stimulating the intrinsic GTPase of p21-Ras-GTP to hydrolyze GTP to GDP, thus inactivating p21-Ras.
- P21-Ras is a key component of many growth factor signaling pathways, and neurofibromin acts therefore as a tumor suppressor protein.
- It seems that in the pathogenesis of NF1-associated PCC, the cysteine-serine-rich domain (CSR) of neurofibromin plays a more important role than the GRD.[20]
- In the pathogenesis of PCC in NF1 patients, Knudson's two-hit tumor suppressor model could be applied, resulting in a loss of heterozygosity at tumor level. This process leads to the lack of expression of neurofibromin in PCCs.[21]
Associated conditions
- Pheochromocytoma can be part of other syndromes named multiple endocrine neoplasias (MEN1 and MEN2B), which are autosomal dominant syndromes controlled by RET gene. Pheochromocytoma occurs in 50% of patients with MEN2 as follows:
| MEN1 | MEN2 |
|---|---|
Gross Pathology
On gross pathology, A multinodular and multicentric pattern of growth of pheochromocytoma may be seen.
-
Bilateral pheochromocytoma in MEN2. Gross image.
Microscopic Pathology
On microscopic pathology, Pheochromocytoma typically demonstrates a nesting (Zellballen) pattern on microscopy. This pattern is composed of well-defined clusters of tumor cells containing eosinophilic cytoplasm separated by fibrovascular stroma.
-
Micrograph of pheochromocytoma.
-
Histopathology of adrenal pheochromocytoma. Adrenectomy specimen.
-
Micrograph of pheochromocytoma.
-
Micrograph of pheochromocytoma.
_histopathology.jpg)
_histopathology.jpg)
_histopathology.jpg)
Videos
{{#ev:youtube|7yjxG3KmX98}}
References
- ↑ Goldstein RE, O'Neill JA, Holcomb GW, Morgan WM, Neblett WW, Oates JA; et al. (1999). "Clinical experience over 48 years with pheochromocytoma". Ann Surg. 229 (6): 755–64, discussion 764-6. PMC 1420821. PMID 10363888.
- ↑ Raz I, Katz A, Spencer MK (1991). "Epinephrine inhibits insulin-mediated glycogenesis but enhances glycolysis in human skeletal muscle". Am J Physiol. 260 (3 Pt 1): E430–5. PMID 1900669.
- ↑ Arnall DA, Marker JC, Conlee RK, Winder WW (1986). "Effect of infusing epinephrine on liver and muscle glycogenolysis during exercise in rats". Am J Physiol. 250 (6 Pt 1): E641–9. PMID 3521311.
- ↑ Webb TA, Sheps SG, Carney JA (1980). "Differences between sporadic pheochromocytoma and pheochromocytoma in multiple endocrime neoplasia, type 2". Am. J. Surg. Pathol. 4 (2): 121–6. PMID 6103678.
- ↑ Yee JK, Moores JC, Jolly DJ, Wolff JA, Respess JG, Friedmann T (1987). "Gene expression from transcriptionally disabled retroviral vectors". Proc. Natl. Acad. Sci. U.S.A. 84 (15): 5197–201. PMC 298821. PMID 3474647.
- ↑ Shuch B, Ricketts CJ, Metwalli AR, Pacak K, Linehan WM (2014). "The genetic basis of pheochromocytoma and paraganglioma: implications for management". Urology. 83 (6): 1225–32. doi:10.1016/j.urology.2014.01.007. PMC 4572836. PMID 24642075.
- ↑ King KS, Pacak K (2014). "Familial pheochromocytomas and paragangliomas". Mol Cell Endocrinol. 386 (1–2): 92–100. doi:10.1016/j.mce.2013.07.032. PMC 3917973. PMID 23933153.
- ↑ Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M; et al. (2004). "Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations". JAMA. 292 (8): 943–51. doi:10.1001/jama.292.8.943. PMID 15328326.
- ↑ Zbar B, Kishida T, Chen F, Schmidt L, Maher ER, Richards FM; et al. (1996). "Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan". Hum Mutat. 8 (4): 348–57. doi:10.1002/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.0.CO;2-3. PMID 8956040.
- ↑ Kaelin WG (2002). "Molecular basis of the VHL hereditary cancer syndrome". Nat Rev Cancer. 2 (9): 673–82. doi:10.1038/nrc885. PMID 12209156.
- ↑ Barry RE, Krek W (2004). "The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis". Trends Mol Med. 10 (9): 466–72. doi:10.1016/j.molmed.2004.07.008. PMID 15350900.
- ↑ Neumann HP, Bender BU (1998). "Genotype-phenotype correlations in von Hippel-Lindau disease". J Intern Med. 243 (6): 541–5. PMID 9681856.
- ↑ Maher ER, Webster AR, Richards FM, Green JS, Crossey PA, Payne SJ; et al. (1996). "Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations". J Med Genet. 33 (4): 328–32. PMC 1050584. PMID 8730290.
- ↑ Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JB, Gardner E; et al. (1994). "Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC". Nat Genet. 6 (1): 70–4. doi:10.1038/ng0194-70. PMID 7907913.
- ↑ Hansford JR, Mulligan LM (2000). "Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis". J Med Genet. 37 (11): 817–27. PMC 1734482. PMID 11073534.
- ↑ Asai N, Iwashita T, Matsuyama M, Takahashi M (1995). "Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations". Mol Cell Biol. 15 (3): 1613–9. PMC 230385. PMID 7532281.
- ↑ Lantieri F, Griseri P, Ceccherini I (2006). "Molecular mechanisms of RET-induced Hirschsprung pathogenesis". Ann Med. 38 (1): 11–9. doi:10.1080/07853890500442758. PMID 16448984.
- ↑ Shen MH, Harper PS, Upadhyaya M (1996). "Molecular genetics of neurofibromatosis type 1 (NF1)". J Med Genet. 33 (1): 2–17. PMC 1051805. PMID 8825042.
- ↑ Brannan CI, Perkins AS, Vogel KS, Ratner N, Nordlund ML, Reid SW; et al. (1994). "Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues". Genes Dev. 8 (9): 1019–29. PMID 7926784.
- ↑ Bausch B, Borozdin W, Mautner VF, Hoffmann MM, Boehm D, Robledo M; et al. (2007). "Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1". J Clin Endocrinol Metab. 92 (7): 2784–92. doi:10.1210/jc.2006-2833. PMID 17426081.
- ↑ Gutmann DH, Cole JL, Stone WJ, Ponder BA, Collins FS (1994). "Loss of neurofibromin in adrenal gland tumors from patients with neurofibromatosis type I." Genes Chromosomes Cancer. 10 (1): 55–8. PMID 7519874.